Company Monitoring Page for Sandoz

latest headlines for company on cafepharma

Aurobindo bids $1.6B for Novartis' U.S. dermatology generics: report
Fierce Pharma
Mon, 05/7/18 - 10:53 pm
Tags:
Aurobindo, Novartis, Sandoz, M&A, dermatology, India
Impax Laboratories Agrees to Settle Antitrust Lawsuit
CP Wire
Mon, 04/30/18 - 06:46 pm
Tags:
Impax Laboratories, Solodyn, antitrust, Medicis, Lupin, Sandoz
No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging
Endpoints
Thu, 02/8/18 - 11:18 am
Tags:
GSK, R&D, Pharma CEOs, Emma Walmsley, Advair, Novartis, Sandoz, Gilead Sciences, HIV
FDA rejects Novartis’ Advair generic, leaving GSK without rival
Drug Delivery Business News
Thu, 02/8/18 - 09:17 am
Tags:
FDA, Novartis, Advair, generics, GSK, Sandoz
Novartis aims for US approval of Humira biosimilar
Biopharma Dive
Wed, 01/17/18 - 09:55 pm
Tags:
Novartis, Humira, biosimilars, AbbVie, Sandoz
Allergan says court affirms patent loss to Sandoz on eye drug
Reuters
Sat, 12/23/17 - 11:33 pm
Tags:
Allergan, patents, Sandoz, generics, Combigan
Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster
Fierce Pharma
Fri, 12/8/17 - 10:41 am
Tags:
Novartis, Neulasta, biosimilars, Amgen, Sandoz, FDA
Novartis looks at offloading its generic pills business in U.S. as market continues to decline
Fierce Pharma
Mon, 12/4/17 - 11:39 am
Tags:
Novartis, generics, Sandoz, M&A
Amazon in talks with generic drugmakers including Mylan, Sandoz about pharma play: report
Fierce Pharma
Sun, 12/3/17 - 11:35 am
Tags:
Amazon, generics, Sandoz, Mylan Labs
Sandoz head sees biosimilars as the light in the generics storm
Fierce Pharma
Thu, 11/30/17 - 11:05 am
Tags:
generics, biosimilars, Sandoz, Peter Goldschmidt
Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars
Endpoints
Wed, 10/25/17 - 10:59 am
Tags:
Sandoz, Novartis, FDA, biosimilars
Novartis division closing Broomfield operations
Broomfield Enterprise, Colorado
Tue, 10/17/17 - 09:46 am
Tags:
Novartis, drug manufacturing, Sandoz, generics
Lilly wards off another Alimta patent challenge, this time through IPR
Fierce Pharma
Fri, 10/6/17 - 11:42 am
Tags:
Eli Lilly, Alimta, patents, IPR, lung cancer, Neptune, generics, Novartis, Sandoz
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Fri, 07/14/17 - 07:58 am
Tags:
Novartis, rheumatoid arthritis, generics, Sandoz, Amgen, Enbrel, JNJ, Remicade, AbbVie, Humira
Biogen aims to block Tecfidera generics with flurry of lawsuits
Bizjournals.com
Tue, 07/4/17 - 11:22 pm
Tags:
Biogen, Tecfidera, generics, MS, multiple sclerosis, Novartis, Sandoz, Mylan Labs
Novartis scores second biosimilar approval in two weeks
BioPharma Dive
Thu, 06/29/17 - 09:43 am
Tags:
Novartis, biosimilars, Enbrel, Europe, Sandoz, Erelzi, Roche, Rituxan
Novartis wins another biosimilar round with an OK for its Rituxan copycat
Endpoints
Mon, 06/19/17 - 03:16 pm
Tags:
Novartis, biosimilars, Rituxan, Roche, Sandoz
Novartis pushes further into pain with Durect deal
BioPharma Dive
Tue, 05/9/17 - 10:45 pm
Tags:
Novartis, Durect, Sandoz, biosimilars, generics, Posimir, R&D
The Demise of the BPCIA Patent Dance?
FDA Law Blog
Fri, 03/3/17 - 09:40 am
Tags:
BPCIA, patents, Genentech, Amgen, Sandoz, Avastin
In Amgen-Sandoz SCOTUS case, biosim makers lambaste ruling's 6-month exclusivity gift
Fierce Pharma
Wed, 02/22/17 - 09:44 am
Tags:
Amgen, Sandoz, Supreme Court, biosimilars

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.